Abstract

BackgroundOne of the most frequent desires of patients with polymyalgia rheumatica (PMR) is to individualize their treatment based on comorbidities, co-medication and prognostic factors. The upcoming ACR/EULAR guidelines for the...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
SP0038 Review of the Key Evidence Supporting the New Treatment Guidelines in Polymyalgia Rheumatica
C Dejaco
Annals of the Rheumatic Diseases | VOL. 73
C DejacoC Dejaco
01 Jun 2014
Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica
Eric L Matteson ... Bhaskar Dasgupta
Annals of the Rheumatic Diseases | VOL. 74
Eric L Matteson, et. al.Eric L Matteson ... Bhaskar Dasgupta
09 Sep 2015
Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate
Fabrizio Cantini ... Giovanni Ciancio
Arthritis & Rheumatism | VOL. 44
Fabrizio Cantini, et. al.Fabrizio Cantini ... Giovanni Ciancio
01 May 2001
Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate.
Giovanni Ciancio ... Fabrizio Rubini
Arthritis and rheumatism | VOL. 44
Giovanni Ciancio, et. al.Giovanni Ciancio ... Fabrizio Rubini
01 Jan 2001
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers